Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5993 DPI versus CHF 5993 pMDI and CHF 1535 pMDI in COPD
2017-004405-41Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium and beclometasone dipropionate + formoterol in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: FEV1 AUC0-12h normalized by time. Started Jan 2018; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrroniumbeclometasone dipropionate + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-004405-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004405-41.